One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Hyperkalemia Treatment Market

[ 英語タイトル ] Hyperkalemia Treatment Market - Growth, Trends, and Forecast (2020 - 2025)


Product Code : MDHC0089122
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 110
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - AstraZeneca PLC
- Ardelyx
- Perrigo Company PLC
- Vifor Pharma Management Ltd
- Sanofi SA
- Relypsa Inc.
- Odan Laboratories Ltd

[Report Description]

The increasing prevalence rates of acute hyperkalemia and chronic hyperkalemia are due to the upsurge in geriatric population, globally. The aging population and advances in medical technology are likely to contribute to the increasing prevalence of heart failure and chronic kidney diseases, and consequently, a larger pool of patients is likely to be at risk for hyperkalemia. According to the data from the World Population Prospects: The 2017 Revision, the number of older people, those aged 60 years or above, is expected to be more than double by 2050 and more than triple by 2100, rising from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100.

Hyperkalemia has been reported in around 5% of the general population, worldwide. According to the National Kidney Foundation, in heart failure patients with chronic kidney disease (CKD), the prevalence of hyperkalemia can be up to 20%, and it is associated with an increased risk of mortality and major adverse cardiovascular events. According to the United States Renal Data System (USRDS) (2018), the overall prevalence of CKD (Stages 1-5) among the adult general population in the United States was 14.8% during 2013-2016.

Potassium is regarded as one of the most effective alkalinizing agents for the treatment of hyperkalemia. Moreover, its use in the management of acute and chronic hyperkalemia, related to advanced medical illness, is considered as the standard care in most parts of the world.

Thus, increase in the number of patients undergoing treatment of hyperkalemia is likely to drive the growth of the market.

Key Market Trends

Chronic Hyperkalemia Dominates the Global Hyperkalemia Treatment Market

Chronic hyperkalemia from impaired renal excretion may involve one or more of the conditions, such as decreased mineralocorticoid activity, decreased distal Na+ delivery, and CCD dysfunction. Considered individually, these pathophysiologic processes generally do not create chronic hyperkalemia, but together their effects become clinically significant.​ Chronic hyperkalemia is one of the most prevalent disease conditions among patients suffering from CKDs. As per the National Kidney Foundation, more than 37 million people in the United States have CKDs, and over 80% of them do not know they have it. ​Moreover, the management of chronic hyperkalemia requires confirmation, increased laboratory surveillance, dietary review and counseling, a review of medications (prescribed, over-the-counter, and herbal), and, if needed, a potassium-lowering medication and/or a diuretic.​ As the kidney function declines, the prevalence in patients with CKDs increases; it ranges from 5% to 50% in the patients.​Overall, the chronic hyperkalemia segment of the market studied is expected to grow over the forecast period. This is expected to be fueled by the increasing prevalence of chronic hyperkalemia, with an upsurge in geriatric population levels and related ailments.​

North America Dominates the Global Hyperkalemia Treatment Market

The presence of leading market players, the high prevalence of disease-related conditions, favorable healthcare policies, and high disposable income of the patients bolster demand for advanced therapeutic options, thereby, are expected to contribute to the dominance of the United States, throughout the forecast period.​ Moreover, the growing incidence of hyperkalemia and the rising number of geriatric population are some major factors aiding the growth of the market. Thus, the huge patient population is anticipated to increase the number of patients who opt for treatment, which, in turn, is expected to support growth in the near future.​ For instance, in the United States, the federal government has been running various awareness campaigns through various initiatives, which is expected to have a positive impact on the market studied. ​Hence, this increasing adoption of a patient-centric approach by healthcare payers is expected to drive the US hyperkalemia treatment market, during the forecast period.​

Competitive Landscape

The hyperkalemia market is consolidated, dominated by a few players. The hyperkalemia market underwent extensive changes with the introduction of Veltassa at the beginning of 2016, which represented the first new therapy for the treatment of hyperkalemia in over 50 years. Few key market players in the market are AstraZeneca PLC, Ardelyx, Vifor Pharma Management Ltd, Sanofi SA, and Perrigo Company PLC.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hyperkalemia
4.2.2 Rising Focus on Research and Development and Increasing Number of Strategic Alliances
4.3 Market Restraints
4.3.1 High Cost of Drugs
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Sodium Zirconium Cyclosilicate
5.1.2 Beta2 Agonist
5.1.3 Sodium Polystyrene Sulfonate
5.1.4 Other Drugs
5.2 By Type of Disease
5.2.1 Acute Hyperkalemia
5.2.2 Chronic Hyperkalemia
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AstraZeneca PLC
6.1.2 Ardelyx
6.1.3 Perrigo Company PLC
6.1.4 Vifor Pharma Management Ltd
6.1.5 Sanofi SA
6.1.6 Relypsa Inc.
6.1.7 Odan Laboratories Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+